1. Comparative efficacy and safety of nivolumab (nivo) vs relevant treatments (txs) in pretreated non-squamous (NSQ) advanced non-small cell lung cancer (aNSCLC): Results from a systematic literature review (SLR) and indirect treatment comparisons (ITCs) of randomized controlled trials (RCTs). (February 2017) Authors: Shrestha, A.; Penrod, J.R.; Reck, M.; Spigel, D.R.; Smiechowski, B.; Bognar, K.; Van Eijndhoven, E.; Makris, C.; Healey, D.; Hertel, N.; Korytowsky, B.; Cope, S.; Vanderpuye-Orgle, J. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S136 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 143TiPIMpower110: Phase III trial of 1L atezolizumab in PD-L1–selected chemotherapy-naive NSCLC. (3rd April 2017) Authors: Jassem, J.; de Marinis, F.; Spigel, D.R.; Lam, S.; Mocci, S.; Sandler, A.; Lopez-Chavez, A.; Deng, Y.; Giaccone, G.; Herbst, R.S. Journal: Annals of oncology Issue: Volume 28(2017)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 3010 Phase, randomized trial (CheckMate 057) of nivolumab (NIVO) vs docetaxel (DOC) in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): Subgroup analyses and patient reported outcomes (PROs). (September 2015) Authors: Horn, L.; Brahmer, J.; Reck, M.; Borghaei, H.; Spigel, D.R.; Steins, M.; Ready, N.E.; Chow, L.Q.; Vokes, E.E.; Felip, E.; Holgado, E.; Barlesi, F.; Kohlhäufl, M.J.; Burgio, M.A.; Fayette, J.; Gettinger, S.N.; Harbison, C.T.; Li, A.; Finckenstein, F.G.; Paz-Ares, L. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S599 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 3094 Nivolumab (NIVO) safety profile: Summary of findings from trials in patients (pts) with advanced squamous (SQ) non-small cell lung cancer (NSCLC). (September 2015) Authors: Gettinger, S.N.; Horn, L.; Ramalingam, S.S.; Spigel, D.R.; Paz-Ares, L.; Paik, P.; Reck, M.; Reckamp, K.; Mazières, J.; Stinchcombe, T.; Lynch, M.; Brahmer, J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S631 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 3090 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or recurrent non-small-cell lung cancer progressing after platinum-based chemotherapy: A phase Ib trial. (September 2015) Authors: Gulley, J.L.; Rajan, A.; Spigel, D.R.; Iannotti, N.; Chandler, J.; Wong, D.J.L.; Leach, J.L.; Edenfield, W.J.; Wang, D.; Bajars, M.; Von Heydebreck, A.; Kelly, K. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S629 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Activity and safety of ipatasertib (ipat) for AKT activating mutation and/ or PTEN loss/loss of function solid tumors from MyTACTIC. (October 2022) Authors: VanderWalde, A.; Spigel, D.R.; Darbonne, W.C.; Yu, W.; Kim, Y.; Whitehead, Z.; Szado, T.; Slater, D.; Zuniga, R.; Arrowsmith, E. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S71 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 148P AdvanTIG-105: Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC). (December 2022) Authors: Zhang, J.; Hussein, M.; Kao, S.C-H.; Clay, T.D.; Singhal, N.; Kim, H.R.; Cho, E.K.; Shim, B.; Lee, Y.; Lee, G-W.; Zhao, J.; Yu, Y.; Sun, M.; Lin, C-B.; Yang, T-Y.; Chang, G-C.; Zheng, H.; Tan, W.; Spigel, D.R. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 2MO First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in metastatic non-small cell lung cancer (mNSCLC): Clinical outcomes and biomarker analyses from CheckMate 592. (December 2022) Authors: Gettinger, S.; Schenker, M.; De Langen, J.; Fischer, J.R.; Morgensztern, D.; Ciuleanu, T-E.; Beck, T.; De Castro Carpeno, J.; Schumann, C.; Yang, X.; Telivala, B.; Deschepper, K.; Nadal, E.; Schalper, K.; Spires, T.; Balli, D.; Nassar, A.; Karam, S.; Bhingare, A.; Spigel, D.R. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. 161P A phase Ib study to evaluate IK-007 in combination with pembrolizumab (pembro) in patients with advanced microsatellite stable (MSS) colorectal cancer (CRC). (December 2022) Authors: Tolcher, A.W.; Spigel, D.R.; Leal, A.D.; Bekaii-Saab, T.; Lingaraj, T.; Talcove-Berko, E.; Ortiz-Otero, N.; Bartolini, W.; Kacena, K.; Chisamore, M.; Santillana, S.L. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Comparative efficacy and safety of nivolumab (nivo) vs relevant treatments (txs) in pretreated non-squamous (NSQ) advanced non-small cell lung cancer (aNSCLC): Results from a systematic literature review (SLR) and indirect treatment comparisons (ITCs) of randomized controlled trials (RCTs). (February 2017) Authors: Shrestha, A.; Penrod, J.R.; Reck, M.; Spigel, D.R.; Smiechowski, B.; Bognar, K.; van Eijndhoven, E.; Makris, C.; Healey, D.; Hertel, N.; Korytowsky, B.; Cope, S.; Vanderpuye-Orgle, J. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S136 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗